Portal de investigación
- Inicio
- Proyectos y Estudios
- ESTUDIO DE FASE 2, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA, LA SEGURIDAD Y LA TOLERABILIDAD DE TAK-935 (OV935) COMO TRATAMIENTO COMPLEMENTARIO EN PACIENTES PEDIÁTRICOS CON ENCEFALOPATÍAS EPILÉPTICAS O DEL DESARROLLO (ELEKTRA).
ESTUDIO DE FASE 2, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA, LA SEGURIDAD Y LA TOLERABILIDAD DE TAK-935 (OV935) COMO TRATAMIENTO COMPLEMENTARIO EN PACIENTES PEDIÁTRICOS CON ENCEFALOPATÍAS EPILÉPTICAS O DEL DESARROLLO (ELEKTRA).
Datos básicos
- Código:
- TAK-935-2002(OV935)
- Protocolo:
- TAK-935-2002(OV935)
- EUDRACT:
- 2018-002484-25
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2019
- Año de finalización:
- 2020
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
12-Month Effectiveness and Tolerability of Brivaracetam in the Real-World: The International EXPERIENCE Pooled Analysis
Villanueva, Vicente; (...); Steinhoff, Bernhard J.
Meeting Abstract. 10.1212/WNL.0000000000201896. 2023
2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11611. 2021
A brain atlas of axonal and synaptic delays based on modelling of cortico-cortical evoked potentials
Lemarechal, Jean-Didier; (...); David, Olivier
Article. 10.1093/brain/awab362. 2022
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro
Article. 10.33393/grhta.2022.2333. 2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya, Neboa; (...); Verde, Luis
Article. 10.1017/S0266462322000459. 2022
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.
de Andrés-Nogales F; (...); Martínez-Olmos J
Article. 10.1007/s41669-020-00201-2. 2020
A new definition and refocus of pharmaceutical care: the Barbate Document
Morillo-Verdugo R; (...); Poveda-Andrés JL
Article. 10.7399/fh.11389. 2020
A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
Hahn, Cecil D.; (...); Dlugos, Dennis
Article. 10.1111/epi.17367. 2022
A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report
Auvin, S; (...); Villanueva, V
Article. 10.1186/s13023-019-1072-y. 2019
A survey of the European Reference Network EpiCARE on clinical practice for selected rare epilepsies.
Baumgartner T; (...); Sadowski K
Article. 10.1002/epi4.12459. 2021
A systematic review of behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate in real-world studies
Steinhoff, Bernhard J.; (...); Villanueva, Vicente
Meeting Abstract. 2021
Academic and employment insertion as a factor related to quality of life in patients with drug-resistant temporal lobe epilepsy.
Catalán-Aguilar J; (...); Cano-López I
Article. 10.33588/rn.7407.2020684. 2022
Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.
Ballesta-López O; (...); Poveda-Andrés JL
Article. 10.1177/1078155220915953. 2020
Analysing criteria for price and reimbursement of orphan drugs in Spain.
Badia, X; (...); Tort, M
Article. 10.7399/fh.11147. 2019
Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/10781552211038518. 2021
Anti-GAD65-related epilepsy and its clinical spectrum
Marin Gracia, M.; (...); Villanueva, V.
Meeting Abstract. 2024
Apuntes en Neurologia: una sintesis de la evidencia en trastornos neurologicos comunes paroxisticos y en trastornos neurodegenerativos.
Toledo M; (...); Villanueva V
Abstract of Published Item. 2018
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Assessment of the Long-Term Efficacy and Safety of Adjunctive Perampanel in Adolescent Patients: Post Hoc Analysis of Open-Label Extension (OLEX) Studies
Pina-Garza, JE; (...); Laurenza, A
Meeting Abstract. 2018
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
Iglesias Gómez R; (...); Poveda Andrés JL
Article. 10.1136/ejhpharm-2021-002741. 2021
Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2018.12.027. 2019
Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.
Steinhoff, Bernhard J; (...); Villanueva, Vicente
Review. 10.1016/j.yebeh.2021.107939. 2021
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; (...); Hernandez D
Article. 10.1111/ctr.14550. 2022
Blood Pressure in Seizures and Epilepsy
Nass, RD; (...); Surges, R
Review. 10.3389/fneur.2019.00501. 2019
BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice
Villanueva, V; (...); BRIVA-LIFE Study Grp
Article. 10.1111/ane.13059. 2019
BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice
Villanueva, V.; (...); Sansa, G.
Meeting Abstract. 2024
BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice.
Villanueva V; (...); Serratosa JM
Article. 10.1002/epi4.13078. 2024
Brivaracetam effectiveness and tolerability in older and younger adults with epilepsy: EXPERIENCE, a pooled analysis of international data from retrospective studies.
Faught, Edward; (...); Villanueva, Vicente
Article. 10.1016/j.yebeh.2024.109922. 2024
Candidate Selection for Implantation: Noninvasive Predictors of Seizure Onset Zone Focality and Surgical Outcome in People with Drug-Resistant Epilepsy Evaluated by Intracranial Video-EEG Monitoring-A Retrospective Cohort Study
Jannone-Pedro, Nicolas; (...); Villanueva, Vicente
Article. 10.1155/2023/3455061. 2023
Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain
Garcia-Penas, JJ; (...); Villanueva-Haba, V
Article. 10.33588/rn.73S01.2021250. 2021
Cannabidiol therapy for refractory epilepsy in paediatric real world setting: What's the benefit?
Smeyers, P.; (...); Hernandez, S.
Meeting Abstract. 2024
Cardiovascular response to stress in patients with drug-resistant epilepsy: preliminary data
Lozano-Garcia, A; (...); Cano-Lopez, I
Article. 10.6018/analesps.483021. 2021
Cenobamate in real-life setting: Final outcomes of an expanded access program
Villanueva-Haba, V.; (...); Massot-Tarrus, A.
Meeting Abstract. 2023
CLINICAL AND ECONOMIC CONSEQUENCES OF EPILEPSY TREATMENT ACROSS INCREMENTAL TREATMENT LINES IN SPAIN: A REAL LIFE DATABASE ANALYSIS
Toledano, R.; (...); Hernandez, I
Meeting Abstract. 2023
Clinical and economic implications of epilepsy management across treatment lines in Spain: a real-life database analysis.
Toledano R; (...); Pérez-Domper P
Article. 10.1007/s00415-023-11958-x. 2023
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical characteristics of patients achieving seizure freedom in a phase 2 trial evaluating adjunctive cenobamate
Brandt, C.; (...); Steinhoff, B.
Meeting Abstract. 2022
Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model
Nogueras, A; (...); Calleja, MA
Letter. 10.1136/ejhpharm-2019-001905. 2019
Clinical Predictors of 12-Month Retention in Patients Treated with Eslicarbazepine Acetate: Real-World Evidence from the Euro-Esli Study
Sales, F; (...); Villanueva, V
Meeting Abstract. 2020
Clinical utility of Epitrack for differentiating profiles and patterns of post-surgical change in memory and quality of life in patients with drug-resistant epilepsy.
Lozano-García A; (...); González-Bono E
Article. 10.1080/23279095.2022.2036990. 2022
Cognitive adverse events of adjunctive eslicarbazepine acetate in children with refractory focal seizures
Smeyers, P.; (...); Gama, H.
Meeting Abstract. 2022
Cognitive and Behavioral Effects of Adjunctive Brivaracetam in Children and Adolescents with Focal Seizures: Final Data From an Open-label Follow-up Trial
Elshoff, Jan-Peer; (...); Smeyers, Patricia
Meeting Abstract. 10.1212/WNL.0000000000201877. 2023
Cognitive phenotypes in patients with drug-resistant temporal lobe epilepsy: Relationships with cortisol and affectivity.
Cano-Lopez, Irene; (...); Gonzalez-Bono, Esperanza
Article. 10.1080/13854046.2024.2375605. 2024
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
Complementary and alternative medicine in epilepsy: A global survey of physicians' opinions.
Asadi-Pooya AA; (...); Jusupova A
Article. 10.1016/j.yebeh.2021.107835. 2021
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
Cortisol and trait anxiety as relevant factors involved in memory performance in people with drug-resistant epilepsy
Cano-Lopez, I; (...); Villanueva, V
Article. 10.1016/j.yebeh.2018.12.022. 2019
COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Gironella, M.; (...); Oyaguez, I
Meeting Abstract. 2019
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
Poveda JL; (...); Torres C
Article. 10.1080/14737167.2019.1635014. 2020
COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN
Bonanad, S; (...); Gonzalez-Dominguez, A
Meeting Abstract. 2020
Costs of the management of hemophilia A with inhibitors in Spain
Bonanad, S; (...); Gonzalez-Dominguez, A
Article. 10.33393/grhta.2021.2234. 2021
COVID-19 prevalence and mortality in people with epilepsy: A nation-wide multicenter study.
Sanchez-Larsen A; (...); Sopelana-Garay D
Article. 10.1016/j.yebeh.2021.108379. 2021
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.
Salinas P; (...); Escaned J
Article. 10.1016/j.carrev.2021.11.015. 2021
Design of two parallel randomized, double-blind, placebo-controlled phase 3 studies to evaluate the safety and efficacy of XEN1101 as adjunctive therapy in the treatment of focal onset epilepsy
Perucca, E.; (...); Beatch, G. N.
Meeting Abstract. 2023
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain.
Angel Calleja, Miguel; (...); Gil, Alicia
Article. 10.1080/14737167.2022.2107507. 2022
Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis
Alvarez-Roman, MT; (...); Badia, X
Article. 10.1177/2284240319880534. 2019
DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
Alvarez, E.; (...); Badia, F. J.
Meeting Abstract. 2019
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
Poveda, J. L.; (...); Vitoria, I
Meeting Abstract. 2019
Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
Badia, X; (...); Poved, JL
Article. 10.1080/21678707.2019.1652163. 2019
Development and validation of the Epilepsy Perceived Stress Inventory for Adults (EPSI-A): A pilot study
Catalan-Aguilar, Judit; (...); Gonzalez-Bono, Esperanza
Article. 10.1016/j.yebeh.2024.110142. 2024
Diagnostic challenges in epilepsy
Hampel, KG; (...); Villanueva, V
Article. 10.33588/rn.6806.2018242. 2019
Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?
Lawthom, C; (...); Villanueva, V
Editorial Material. 10.1007/s40120-018-0111-2. 2018
Drug load and memory during intracarotid amobarbital procedure in epilepsy
Lozano-García A; (...); Villanueva V
Editorial Material. 10.1111/ane.13491. 2021
Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.
Torres Martínez E; (...); Vento M
Article. 10.1016/j.anpedi.2020.03.009. 2020
Effect of concomitant medications on adverse event frequency, severity, and resolution in a cenobamate open-label trial
Steinhoff, B.; (...); Villanueva, V.
Meeting Abstract. 2024
Effectiveness and safety of perampanel in elderly epilepsy patients (aged >= 65 years) treated in everyday clinical practice
McMurray, Rob; (...); Villanueva, Vicente
Meeting Abstract. 2021
Effectiveness and Safety/Tolerability of Eslicarbazepine Acetate in Epilepsy Patients Aged = 60 Versus 60Years: A Subanalysis from the Euro-Esli Study.
Lawthom, C; (...); Villanueva, V
Article. 10.1007/s40120-019-0137-0. 2019
Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records.
Villanueva V; (...); Steinhoff BJ
Article. 10.1007/s40263-023-01033-4. 2023
Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis.
Szaflarski, Jerzy P; (...); Villanueva, Vicente
Article. 10.1007/s00415-024-12253-z. 2024
Effectiveness and Tolerability of Perampanel in Epilepsy Patients Treated in Routine Clinical Practice: a Global Pooled Analysis Study
D'Souza, Wendyl; (...); Villanueva, Vicente
Meeting Abstract. 2021
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
Effectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: The PERMIT Extension study.
Wheless J; (...); Villanueva V
Article. 10.1016/j.yebeh.2023.109369. 2023
Effectiveness, safety and tolerability of perampanel in adolescents with focal and generalised seizures: evidence from clinical practice
Gil, Francisco; (...); Villanueva, Vicente
Meeting Abstract. 2021
Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
Piña-Garza JE; (...); Malhotra M
Article. 10.1016/j.yebeh.2019.106876. 2020
Efficacy and safety of cenobamate as adjunctive therapy in patients with uncontrolled focal seizures: results from two double-blind, placebo-controlled, international studies
Steinhoff, BJ; (...); Brandt, C
Meeting Abstract. 2020
Efficacy and safety of stiripentol in the prevention and cessation of status epilepticus: A systematic review.
Specchio N; (...); Trinka E
Article. 10.1002/epi4.13036. 2024
Efficacy of add-on Cenobamate treatment in refractory epilepsy due to Rasmussen's encephalitis.
Schulze-Bonhage A; (...); Villanueva V
Article. 10.1002/epi4.13060. 2024
Efficacy of stiripentol in the management of status epilepticus: A systematic review
Auvin, S.; (...); Trinka, E.
Meeting Abstract. 2024
Efficacy, Safety and Tolerability of Soticlestat (TAK-935/OV935) as Adjunctive Therapy in Pediatric Patients with Dravet Syndrome and Lennox-Gastaut Syndrome (ELEKTRA)
Hahn, Cecil D.; (...); Dlugos, Dennis
Meeting Abstract. 2021
Epilepsy surgery beyond 50?years: Long-term seizure and cognitive outcomes.
Gómez-Ibáñez A; (...); Villanueva-Haba V
Article. 10.1016/j.jns.2020.116872. 2020
Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro-Esli
Holtkamp, M; (...); Villanueva, V
Article. 10.1111/ane.13023. 2019
Eslicarbazepine acetate in epilepsy patients with psychiatric comorbidities and intellectual disability: Clinical practice findings from the Euro-Esli study
Doherty, CP; (...); Villanueva, V
Article. 10.1016/j.jns.2019.04.040. 2019
Eslicarbazepine Acetate in Post-Stroke Epilepsy: A post-hoc Analysis from the Clinical Practice Study Euro-Esli
Sales, F; (...); Fernandes, H
Meeting Abstract. 2019
Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from Euro-Esli.
Sales F; (...); Villanueva V
Article. 10.1111/ane.13323. 2020
EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN
Badia, F. J.; (...); Shepherd, J.
Meeting Abstract. 2019
EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY
F, de Andres-Nogales; (...); Martinez, M.
Meeting Abstract. 2019
Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
Fernandez-Sanchez, M; (...); Poveda-Andres, JL
Article. 10.1002/bdr2.1942. 2021
General Study: 1-Year Real-Life Effectiveness and Tolerability of Perampanel in Idiopathic Generalized Epilepsy
Villanueva, V; (...); Tortosa, D
Meeting Abstract. 2018
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Global pooled analysis of perampanel in epilepsy patients treated in routine clinical practice: the PERMIT study
Villanueva, Vicente; (...); Trinka, Eugen
Meeting Abstract. 2021
Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe.
Cardenal-Muñoz E; (...); Aibar JÁ
Article. 10.1002/epi4.12569. 2022
Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis
Editorial Material. 2022
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.
El-Qutob D; (...); Carrera-Hueso FJ
Article. 10.1016/j.hrtlng.2022.02.003. 2022
Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies
Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo
Article. 10.7399/fh.11729. 2022
Hospitalization budget impact during the COVID-19 pandemic in Spain.
Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.
Article. 10.1186/s13561-021-00340-0. 2021
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA).
Villanueva V; (...); Subías-Labazuy S
Article. 10.1016/j.yebeh.2021.108222. 2021
Impact of antiseizure medication with a very long half-life on long term video-EEG monitoring in focal epilepsy.
Hampel, Kevin G.; (...); Villanueva, Vicente
Article. 10.1016/j.seizure.2023.12.010. 2023
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of COVID-19 on Spanish patients with Dravet syndrome and their caregivers: consequences of lockdown
Munoz, EC; (...); Aibar JA
Article. 10.33588/rn.7302.2021006. 2021
Impact of Polytherapy on Memory Functioning in Patients With Drug-Resistant Epilepsy: The Role of Attention and Executive Functions.
Lozano-Garcia, Alejandro; (...); Gonzalez-Bono, Esperanza
Article. 10.1093/arclin/acad086. 2023
Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
Badia X; (...); Hernández C
Article. 10.1186/s13023-020-01507-4. 2020
Impact of voriconazole plasma concentrations on treatment response in critically ill patients
Ruiz, J; (...); Ramirez, P
Article. 10.1111/jcpt.12817. 2019
Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases
Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL
Article. 10.7399/fh.11262. 2020
Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
Bastida, G; (...); Nos, P
Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Initial monotherapy with eslicarbazepine acetate for the management of adult patients with focal epilepsy in clinical practice: a meta-analysis of observational studies.
Fernandez-Anaya, Silvia; (...); Sarasa, Pilar
Article. 10.1080/00207454.2021.1925667. 2021
Initiating antiepilepsy treatment: An update of expert consensus in Spain.
Villanueva V; (...); Gil-Nagel A
Article. 10.1016/j.yebeh.2020.107540. 2021
Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12842. 2019
Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.
Solana-Altabella A; (...); Poveda JL
Article. 10.1177/1078155220904410. 2020
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP
Article. 10.1136/ejhpharm-2020-002322. 2020
Involvement of mental health professionals in the treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND): results of a multinational European electronic survey
Waltereit, R; (...); Auvin, S
Article. 10.1186/s13023-021-01800-w. 2021
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
La reserva cognitiva como factor modulador del impacto de la cirugía sobre la memoria visual y la denominación en pacientes con epilepsia del lóbulo temporal.
Cano-Lopez, I; (...); Gonzalez-Bono, E
Article. 10.33588/rn.7308.2021109. 2021
Long-Term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures.
Klein, Pavel; (...); Villanueva, Vicente
Article. 10.1212/WNL.0000000000200792. 2022
Long-Term Soticlestat Treatment in Patients with Developmental and/or Epileptic Encephalopathies in the ENDYMION Ongoing Open-Label Extension Study
Hahn, Cecil D.; (...); Dlugos, Dennis
Meeting Abstract. 2021
Long-term, quality of life in epilepsy inventory-31 (QOLIE-31) improvements in adults with focal onset seizures treated with XEN1101 in an ongoing, open-
Brandt, C.; (...); Beatch, G. N.
Meeting Abstract. 2024
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Management of patients with Dravet syndrome in real-world clinical practice across five countries in Europe: Impact of treatment-related burden on health outcomes
Ross, E.; (...); Andrews, J. S.
Meeting Abstract. 2024
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Article. 10.3390/cancers14030596. 2022
Metyrapone as treatment in the neonatal McCune-Albright syndrome
de Mingo, Carmen; (...); Garcia-Robles, Ana
Article. 10.1515/jpem-2020-0036. 2020
Mitochondrial developmental encephalopathy with bilateral optic neuropathy related to homozygous variants in IMMT gene.
Marco-Hernández AV; (...); Martínez-Castellano F
Article. 10.1111/cge.14093. 2022
Monitoring coagulation factors during surgery. A systematic review
Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11766. 2021
Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).
Valero-García S; (...); Delgado-Sánchez O
Article. 10.7399/fh.11655. 2021
MONOZEB: Long-term observational study of eslicarbazepine acetate monotherapy
Villanueva, V; (...); Hampel, K
Article. 10.1016/j.yebeh.2019.05.003. 2019
Multichannel dynamic modeling of non-Gaussian mixtures
Safont, G; (...); Villanueva, V
Article. 10.1016/j.patcog.2019.04.022. 2019
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Gomez-Cebrian, N; (...); Pineda-Lucena, A
Review. 10.3390/cancers13184544. 2021
National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)
Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel
Correction. 10.7399/fh.11740. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
Villanueva V; (...); López-González FJ
Review. 10.33588/rn.72S01.2021017. 2021
Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain.
Villanueva, Vicente; (...); Gil, Alicia
Article. 10.1016/j.yebeh.2022.109054. 2023
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
Papel del acetato de eslicarbazepina en el tratamiento de la epilepsia de origen focal en la edad pediátrica: consideraciones prácticas.
García-Peñas JJ; (...); Aparicio J
Review. 10.33588/rn.71s01.2020562. 2020
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol
Garcia-Robles, Ana; (...); Carrascosa, MA
Article. 10.3389/fped.2020.00372. 2020
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Correction. 10.3389/fped.2021.834454. 2022
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project
Morillo-Verdugo, R; (...); Diaz-Olmo, J
Article. 10.7399/fh.11719. 2021
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.
Morillo-Verdugo R; (...); Díaz-Olmo J
Article. 2021
Patient profile, management, and quality of life associated with Dravet syndrome: a cross-sectional, multicentre study of 80 patients in Spain.
Gil-Nagel, Antonio, Sanchez-Carpintero, Rocio, Villanueva, Vicente
Article. 10.1038/s41598-023-30273-z. 2023
Perampanel as Early Add on Therapy for Epilepsy Patients with Focal -Onset an Generalized-Onset Seizures Treated in Clinical Practice(p1-1.Virtua)
Santamarina, Estevo; (...); Villanueva, Vicente
Meeting Abstract. 2022
Perampanel as Early Add on Therapy for Epilepsy Patients with Focal -Onset and Generalized-Onset Seizures Treated in Clinical Practice(p1-1.Virtual)
Santamarina, Estevo; (...); Villanueva, Vicente
Meeting Abstract. 2022
Perampanel as early add-on therapy for epilepsy patients with focal and generalised seizures treated in clinical practice
Santamarina Perez, Estevo; (...); Villanueva, Vicente
Meeting Abstract. 2021
Perampanel as Early Add-on Therapy for Epilepsy Patients with Focal and Generalized Seizures Treated in Clinical Practice
Santamarina, Estevo; (...); Villanueva, Vicente
Meeting Abstract. 2021
Perampanel for the treatment of Asian people with epilepsy: Real-world evidence from the PERMIT extension study.
Wu, Tony; (...); Villanueva, Vicente
Article. 10.1016/j.jns.2024.123173. 2024
Perampanel for the treatment of epilepsy with genetic aetiology: Real-world evidence from the PERMIT Extension study.
Delanty N; (...); Villanueva V
Article. 10.1016/j.eplepsyres.2024.107339. 2024
Perampanel for the treatment of focal and generalised seizures in patients with epilepsy with tumour aetiology: evidence from clinical practice
Coppola, Antonietta; (...); Villanueva, Vicente
Meeting Abstract. 2021
Perampanel for the treatment of patients with myoclonic seizures in clinical practice: Evidence from the PERMIT study
D'Souza, Wendyl; (...); Villanueva, Vicente
Article. 10.1016/j.seizure.2022.06.008. 2022
Perampanel for the Treatment of People with Idiopathic Generalized Epilepsy in Clinical Practice.
Trinka E; (...); Villanueva V
Article. 10.1111/epi.17631. 2023
Perampanel for treatment of epilepsy with tumour, vascular or traumatic brain injury aetiology: Evidence from the PERMIT extension study
Strzelczyk, A.; (...); Villanueva, V.
Meeting Abstract. 2024
Perampanel for treatment of focal and generalized epilepsy in everyday clinical practice: Evidence from permit extension
Trinka, Eugen; (...); Villanueva, Vicente
Meeting Abstract. 10.1016/j.jns.2023.121561. 2023
Perampanel for Treatment of People with a Range of Epilepsy Aetiologies in Clinical Practice: Evidence from the PERMIT Extension Study.
Strzelczyk, Adam; (...); Villanueva, Vicente
Article. 10.1007/s40120-024-00618-5. 2024
Perampanel in adult epilepsy patients treated in everyday clinical practice: results from an interim pooled analysis of real-world studies
Strzelczyk, Adam; (...); Villanueva, Vicente
Meeting Abstract. 2021
Perampanel Monotherapy for Focal and Generalized Epilepsy in Clinical Practice
Chinvarun, Yotin; (...); Villanueva, Vicente
Article. 10.1155/2023/2852853. 2023
Perampanel monotherapy in epilepsy patients with focal and generalised seizures: real-world experience
Alsaadi, Taoufik; (...); Villanueva, Vicente
Meeting Abstract. 2021
Perampanel outcomes at different stages of treatment in people with focal and generalized epilepsy treated in clinical practice: Evidence from the PERMIT study.
Liguori, Claudio; (...); Villanueva, Vicente
Article. 10.3389/fneur.2023.1120150. 2023
PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice
Villanueva, Vicente; (...); Trinka, Eugen
Article. 10.1007/s00415-021-10751-y. 2021
Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy
Margusino-Framiñán L; (...); Morillo-Verdugo R
Article. 10.7399/fh.11498. 2020
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacometabolomics by NMR in Oncology: A Systematic Review.
Gómez-Cebrián N; (...); Pineda-Lucena A
Article. 10.3390/ph14101015. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
Vericat, JEM; (...); Iorio, A
Meeting Abstract. 2020
Predictors of seizure freedom, response and retention after 12 months of treatment with eslicarbazepine acetate: A post-hoc analysis of the Euro-Esli study
Sales, F; (...); Villanueva, V
Article. 10.1016/j.eplepsyres.2021.106653. 2021
PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019
Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.
García-Robles A; (...); Aguar-Carrascosa M
Letter. 10.1016/j.anpedi.2020.06.008. 2021
Preparation and administration of insulin infusions in neonatology: A national survey.
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Article. 10.1016/j.anpede.2020.06.015. 2021
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Presurgical Use of Cenobamate for Adult and Pediatric Patients Referred for Epilepsy Surgery: Expert Panel Recommendations.
Laxer KD; (...); Villanueva V
Article. 10.1007/s40120-024-00651-4. 2024
Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review
Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11780. 2021
Prognostic value of the 5-SENSE Score to predict focality of the seizure-onset zone as assessed by stereoelectroencephalography: a prospective international multicentre validation study.
Astner-Rohracher, Alexandra; (...); Frauscher, Birgit
Article. 10.1136/bmjno-2024-000765. 2024
Proposed Recommendations for the Management of Depression in Adults with Epilepsy: An Expert Consensus.
Villanueva, Vicente; (...); Bobes, Julio
Article. 10.1007/s40120-023-00437-0. 2023
Prospective study of cenobamate on cognition, affectivity and quality of life in focal epilepsy.
Catalan-Aguilar, Judit; (...); Villanueva, Vicente
Article. 10.1002/epi4.12857. 2023
Real-life evidence about the use of intravenous brivaracetam in urgent seizures: The BRIV-IV study.
Villanueva V; (...); Escalza I
Article. 10.1016/j.yebeh.2023.109384. 2023
Real-Time Localization of Epileptogenic Foci EEG Signals: An FPGA-Based Implementation
Frances-Villora, JV; (...); Guerrero-Martinez, JF
Article. 10.3390/app10030827. 2020
Real-world clinical burden of non-seizure symptoms among patients with dravet syndrome or Lennox- Gastaut syndrome in Europe: Results from a global multinational survey
Berthoz, F. Truong; (...); Andrews, J. S.
Meeting Abstract. 2024
Real-World Experience of Perampanel Monotherapy in Epilepsy Patients with Focal-Onset and Generalized-Onset Seizures
Alsaadi, Taoufik; (...); Villanueva, Vicente
Meeting Abstract. 2022
Real-world experience of treating patients aged <12 years with perampanel
Auvin, Stephane; (...); Villanueva, Vicente
Meeting Abstract. 2021
Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an Expanded Access Program.
Villanueva, Vicente; (...); Rodriguez-Uranga, Juan J.
Article. 10.1002/epi4.12757. 2023
Refractory status epilepticus due to vitamin B6 deficit in a Parkinson's disease patient in treatment with levodopa/carbidopa intestinal gel
Baviera-Munoz, R.; (...); Martinez-Torres, I.
Letter. 10.1016/j.nrl.2021.10.002. 2022
Refractory status epilepticus due to vitamin B6 deficit in a Parkinson's disease patient in treatment with levodopa/carbidopa intestinal gel.
Baviera-Muñoz R; (...); Martinez-Torres I
Article. 10.1016/j.nrleng.2021.10.002. 2022
Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.
Nabbout, Rima; (...); Cross, J. Helen
Article. 10.1016/j.seizure.2023.05.003. 2023
Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice.
Rocamora R; (...); Villanueva V
Article. 10.1016/j.seizure.2019.12.022. 2020
SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11565. 2020
Severe Communication Delays Are Independent of Seizure Burden and Persist Despite Contemporary Treatments in SCN1A+ Dravet Syndrome: Insights from the ENVISION Natural History Study.
Perry, M. Scott; (...); Rico, Salvador
Article. 10.1111/epi.17850. 2023
SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization
Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis
Article. 10.1111/jcpt.13703. 2022
Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures.
Carreño M; (...); Villanueva V
Article. 10.1002/epi4.12936. 2024
Stereoencephalography-guided thermocoagulation: Experience in our centre
De Castro Garcia, A. Celdran; (...); Villanueva, V.
Meeting Abstract. 2024
Stress phenotypes in epilepsy: impact on cognitive functioning and quality of life.
Catalán-Aguilar J; (...); Cano-López I
Article. 10.3389/fpsyg.2023.1100101. 2023
Sustained =90% response and seizure freedom in patients with focal-onset seizures treated with cenobamate
Alvarez-Baron, E., Thangavelu, K., Villanueva, V.
Meeting Abstract. 2023
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; (...); Gil A
Article. 10.1016/j.yebeh.2022.108711. 2022
The Charlotte Project: Recommendations for patient-reported outcomes and clinical parameters in Dravet syndrome through a qualitative and Delphi consensus study.
Aledo-Serrano Á; (...); Sánchez-Carpintero R
Article. 10.3389/fneur.2022.975034. 2022
The number of anti-seizure medications mediates the relationship between cognitive performance and quality of life in temporal lobe epilepsy.
Lozano-García A; (...); Cano-López I
Article. 10.1016/j.yebeh.2020.107699. 2021
The relationship between memory and quality of life is mediated by trait anxiety in patients with temporal lobe epilepsy.
Cano-Lopez, Irene; (...); Gonzalez-Bono, Esperanza
Article. 10.1007/s11136-022-03306-9. 2022
The significance of very long half-life in the context of antiseizure medication withdrawal during long-term video-EEG monitoring.
Hampel, Kevin Gil; (...); Villanueva, Vicente
Letter. 10.1016/j.seizure.2024.01.006. 2024
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
Therapeutic strategies during cenobamate treatment initiation: Delphi panel recommendations
Steinhoff, Bernhard J.; (...); Villanueva, Vicente
Review. 10.1177/17562864241256733. 2024
Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials
Privitera, M; (...); VanLandingham, K
Article. 10.1111/epi.16878. 2021
Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
Cohen, JM; (...); Zuberi, SM
Article. 10.1111/epi.16974. 2021
Time to Onset of Efficacy of Cannabidiol (CBD) During Titration in Patients with Lennox-Gastaut Syndrome and Dravet Syndrome Enrolled in Three Randomized Controlled Trials
Mazurkiewicz-Beldzinska, M; (...); Knappertz, V
Meeting Abstract. 2019
Time To Onset Of Efficacy Of Cannabidiol (CBD) During Titration In Patients With Lennox-Gastaut Syndrome Or Dravet Syndrome Enrolled In Three Randomised Controlled Trials
Mazurkiewicz-Beldzinska, M; (...); Knappertz, V
Meeting Abstract. 2019
Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.
Marques MR; (...); Mangas-Sanjuan V
Article. 10.1111/apa.14944. 2020
Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy
Del Rio-Bermudez, C; (...); Poveda, JL
Editorial Material. 10.1186/s40545-020-00276-6. 2020
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
Treatment patterns and disease burden among patients with Lennox- Gastaut syndrome in Europe: A real-world survey
Benitez, A.; (...); Andrews, J. S.
Meeting Abstract. 2024
Triplication of the PCDH19 Gene as a Novel Disease Mechanism Leading to Epileptic Encephalopathy Resembling Loss-of-Function Pathogenic Variants.
Gabaldón-Albero A; (...); Martínez F
Article. 10.3390/genes15101312. 2024
Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Bejar, S; (...); Mateu, PN
Meeting Abstract. 2020
Unravelling the mysteries of sudden unexpected death in epilepsy (vol 34, pg 527, 2019)
Hampel, K. G., Rocamora, R., Quesada, C. M.
Correction. 10.1016/j.nrl.2021.11.004. 2022
USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Dominguez Hernandez, L.; (...); Gomez Segui, I
Meeting Abstract. 2019
Use of Stiripentol in Patients with Dravet Syndrome: Common Practice Among Experts in Spain.
Garcia-Penas, Juan Jose; (...); Sanchez-Carpintero, Rocio
Article. 10.1007/s40120-024-00677-8. 2024
Use of Tachosil (R) as an adjuvant therapeutic option in neurotrophic keratopathy in order to prevent perforation
Rahhal-Ortuno, M; (...); Cisneros-Lanuza, AL
Article. 10.4103/ijo.IJO_1573_18. 2019
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023
What do 90-99% responder rates mean in patients treated with cenobamate: results from an open label extension study
Serratosa, J.; (...); Villanueva, V.
Meeting Abstract. 2023
What do 90-99% responder rates mean in patients treated with cenobamate: results from the open label extension (OLE) of study C017?
Serratosa, J. M.; (...); Villanueva, V.
Meeting Abstract. 2023